Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00376935 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT00376935 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 99 participants.
The verdict
NCT00376935, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
Palifermin is a modified version of a naturally occurring human growth factor that is currently approved by the FDA to treat blood cancers. The purpose of this study is to determine whether palifermin can increase CD4 counts in treatment-experienced HIV infected adults.
Interventions
- DRUG Palifermin
- DRUG Palifermin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00376935
The ClinicalTrials.gov registry entry for NCT00376935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Palifermin is the first listed.
NCT00376935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00376935 about?
NCT00376935 is a clinical study titled "Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults". Palifermin is a modified version of a naturally occurring human growth factor that is currently approved by the FDA to treat blood cancers. The purpose of this study is to determine whether palifermin can increase CD4 counts in treatment-experienced HIV infected adults.
What is the current status of trial NCT00376935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2006-12. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00376935?
The interventions under investigation include: Palifermin (DRUG), Palifermin placebo (DRUG).
Who is sponsoring clinical trial NCT00376935?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.